Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme

Ruth E. Langley(MRC Clinical Trials Unit at UCL), Mahesh Parmar(University College London), Angus Robinson(Royal Sussex County Hospital), Roger Kockelbergh(University Hospitals of Leicester NHS Trust), J. Jeffrey Marshall(MRC Clinical Trials Unit at UCL), Marc Laniado(Wexham Park Hospital), Archie Macnair(MRC Clinical Trials Unit at UCL), S. Williams(Royal Derby Hospital), Caroline Manetta(University Hospitals Sussex NHS Foundation Trust), Stephen McKay(Beatson West of Scotland Cancer Centre), Edgar Páez(Freeman Hospital), Abdulla Alhasso(Beatson West of Scotland Cancer Centre), Melanie Weiß(MRC Clinical Trials Unit at UCL), Matthew Nankivell(MRC Clinical Trials Unit at UCL), Silvia Forcat(MRC Clinical Trials Unit at UCL), Noel W. Clarke(The Christie NHS Foundation Trust), Jane Worlding(University Hospitals Coventry and Warwickshire NHS Trust), Iqtedar A Muazzam(Castle Hill Hospital), Sanjeev Madaan(Dartford And Gravesham NHS Trust), Stuart D. Rosen(Royal Brompton & Harefield NHS Foundation Trust), Stephen Mangar(Imperial College Healthcare NHS Trust), Duncan C. Gilbert(Royal Sussex County Hospital), Howard Kynaston(Cardiff University), John V Deighan(MRC Clinical Trials Unit at UCL), Christopher Scrase(East Suffolk and North Essex NHS Foundation Trust), Jonathan McFarlane(Royal United Hospital Bath NHS Trust), A. Pope(Imperial College Healthcare NHS Trust), S.K. Sundaram(Mid Yorkshire Hospitals NHS Trust), Sanjay Dixit(Scunthorpe General Hospital), Trinh Duong(MRC Clinical Trials Unit at UCL), Gerald N. Collins(East Cheshire NHS Trust)
The Lancet
February 1, 2021
10.1016/s0140-6736(21)00100-8
Cited by 49

Related Papers

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
|The Lancet|2015|2k
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
|New England Journal of Medicine|2017|1.8k
Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial
|The Lancet|2009|1.5k
Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial
|The Lancet|2009|1.1k
Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology Society
|European Journal of Heart Failure|2020|767